{
  "timestamp": "2026-01-19T10:00:00Z",
  "skill": "open",
  "trade_id": "TRD-20260119-WRB-INSIDER",
  "ticker": "WRB",
  "archetype": "insider",
  "outcome": "SUCCESS",
  "metrics": {
    "entry_price": 68.00,
    "shares": 18,
    "position_value": 1224,
    "position_pct": 0.049,
    "archetype_max_pct": 0.05,
    "score": 9.5,
    "binding_constraint": "archetype_cap",
    "stop_price": 62.00,
    "target_price": 84.00
  },
  "data_sources": ["Web search (current price)", "CONFIG.json", "WRB watchlist"],
  "execution_time_ms": 3500,
  "notes": "BUY decision executed. High conviction insider signal from Mitsui Sumitomo strategic stake increase. Score 9.5. Limit order to be placed at bid/ask midpoint (~$68.00). Q4 earnings Jan 26."
}
{
  "timestamp": "2026-01-19T22:35:00Z",
  "skill": "open",
  "trade_id": "TRD-20260119-BILL-ACTIVIST",
  "ticker": "BILL",
  "archetype": "activist",
  "outcome": "SUCCESS",
  "metrics": {
    "entry_price": 48.25,
    "shares": 31,
    "position_value": 1495.75,
    "position_pct": 0.0598,
    "archetype_max_pct": 0.06,
    "score": 9.5,
    "binding_constraint": "archetype_cap",
    "stop_price": 40.00,
    "target_price": 61.00
  },
  "data_sources": ["Web search", "CONFIG.json", "BILL watchlist"],
  "execution_time_ms": 2800,
  "notes": "BUY decision executed via bulk-process. Dual Tier-1 activists (Starboard 8.5%, Elliott 5%+). Cooperation agreement in place. Company exploring strategic alternatives/sale. Stock down 40% YTD."
}
{
  "timestamp": "2026-01-19T22:35:00Z",
  "skill": "open",
  "trade_id": "TRD-20260119-RGNX-PDUFA",
  "ticker": "RGNX",
  "archetype": "pdufa",
  "outcome": "SUCCESS",
  "metrics": {
    "entry_price": 13.62,
    "shares": 27,
    "position_value": 367.74,
    "position_pct": 0.0147,
    "archetype_max_pct": 0.015,
    "score": 9.0,
    "binding_constraint": "archetype_cap",
    "stop_price": 8.00,
    "target_price": 30.78
  },
  "data_sources": ["Stooq", "CONFIG.json", "RGNX watchlist"],
  "execution_time_ms": 2500,
  "notes": "BUY decision executed via bulk-process. RGX-121 gene therapy for Hunter Syndrome. PDUFA Feb 8, 2026 (20 days). FDA inspections passed. Positive 12-month data submitted. 105% upside to analyst target."
}
